Natco Pharma, Hetero seek marketing authorisation for anti-Covid drug molnupiravir

​Natco has conducted Phase III trials of molnupiravir and submitted the trial results to the drug regulator this month. ​"We have submitted phase-III clinical trial results of Molnupiravir to DCGI and we are awaiting for their marketing permission,” Natco said in response to an email.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3Cpb40G
via IFTTT